Replies to post #32749 on Humanigen Inc (fka HGENQ)

[cowtown jay]

Where did I see something like that? Oh, yeah, under the "Recommendation" section of the NIH guidelines for treating Covid 19.

"Recommendation
There is insufficient evidence for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of GM-CSF inhibitors for the treatment of hospitalized patients with COVID-19."

Their "Rationale" for failing to Recommend lenz?

"Preliminary data from a double-blind, placebo-controlled randomized trial of lenzilumab did show a significant improvement in the primary endpoint of ventilator-free survival through Day 28 among those who received the GM-CSF inhibitor. However, preliminary data from a large, double-blind randomized trial of otilimab (primary endpoint: alive and free of respiratory failure at Day 28) and published results of a small, double-blind randomized trial of mavrilimumab (primary endpoint: proportion alive and off supplemental oxygen at Day 14) did not show a survival benefit for the GM-CSF inhibitors compared to placebo."

So it makes sense to you that the NIH recognizes lenzilumab's success, but doesn't Recommend lenz because otilimab and mavrilimumab weren't successful?

https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/gm-csf-inhibitors/